# A Study to Evaluate SAGE-217 in Participants With Moderate to Severe Major Depressive Disorder

> **NCT03000530** · PHASE2 · COMPLETED · sponsor: **Biogen** · enrollment: 102 (actual)

## Conditions studied

- Major Depression

## Interventions

- **DRUG:** SAGE-217
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03000530
- **Lead sponsor:** Biogen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-12-07
- **Primary completion:** 2017-10-04
- **Final completion:** 2017-11-08
- **Target enrollment:** 102 (ACTUAL)
- **Last updated:** 2023-11-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03000530

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03000530, "A Study to Evaluate SAGE-217 in Participants With Moderate to Severe Major Depressive Disorder". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03000530. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*